SK Biopharmaceuticals has added a second preclinical Parkinson’s disease therapy to its pipeline courtesy of a $314.8 million biobucks deal…

A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting…

Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis program after flunking a phase 2 trial.

Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 billion biobucks pact with…

Novartis is paying Sironax $125 million to take up its option on a brain delivery platform, gaining control of technology…

Sling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease through…

After teasing a new initiative to speed up early-stage clinical trials over the summer, the FDA today opened a pilot…

Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a phase…

Eli Lilly’s ongoing attempt to strengthen its genetic medicine offering has seen the company pledge up to $237 million in…

Sionna Therapeutics is laying off almost half its workforce as the company recovers from the failure of its closely watched…